Novel anticancer strategies / / Hassan Bousbaa, editor.

• TeilnehmendeR: Bousbaa, Hassan,
• Place / Publishing House: Basel : : MDPI,, [2023]; ©2023
• Year of Publication: 2023
• Language: English
• Physical Description: 1 online resource

Novel Anticancer Strategies reviews important findings and updates within the cancer therapy field, of great interest to those in academic research studying the development and validation of novel anticancer approaches. The Editor invited preeminent specialists to contribute to original and review articles devoted to key areas of major progress and expectations. Key features: Nanoparticle-based drug delivery in cancer therapy; Extracellular vesicles for anticancer drug delivery; Peptide-based drug conjugates; Cancer stem cells as a valuable target to eradicate tumor relapse; Spheroids in preclinical model for cancer research; and cancer immunotherapy.

Table of Contents

About the Editor vii -- Hassan Bousbaa -- Novel Anticancer Strategies -- Reprinted from: Pharmaceutics 2021, 13, 275, doi:10.3390/pharmaceutics13020275 1 -- Khaled AbouAitah and Witold Lojkowski -- Delivery of Natural Agents by Means of Mesoporous Silica Nanospheres as a Promising -- Anticancer Strategy -- Reprinted from: Pharmaceutics 2021, 13, 143, doi:10.3390/pharmaceutics13020143 5 -- Sibusiso Alven and Blessing Atim Aderibigbe -- The Therapeutic Efficacy of Dendrimer and Micelle Formulations for Breast Cancer Treatment -- Reprinted from: Pharmaceutics 2020, 12, 1212, doi:10.3390/pharmaceutics12121212 57 -- Ik Sup Jin, Min Jeong Jo, Chun-Woong Park, Youn Bok Chung, Jin-Seok Kim and Dae Hwan -- Shin -- Physicochemical, Pharmacokinetic, and Toxicity Evaluation of Soluplus® Polymeric Micelles -- Encapsulating Fenbendazole -- Reprinted from: Pharmaceutics 2020, 12, 1000, doi:10.3390/pharmaceutics12101000 107 -- Sathishbabu Paranthaman, Meghana Goravinahalli Shivananjegowda, Manohar Mahadev, -- Afrasim Moin, Shivakumar Hagalavadi Nanjappa and Nandakumar Dalavaikodihalli -- Nanjaiyah et al. -- Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management -- Reprinted from: Pharmaceutics 2020, 12, 1198, doi:10.3390/pharmaceutics12121198 123 -- Yongwhan Choi, Hyounkoo Han, Sangmin Jeon, Hong Yeol Yoon, Hyuncheol Kim and Ick -- Chan Kwon et al. -- Deep Tumor Penetration of Doxorubicin-Loaded Glycol Chitosan Nanoparticles Using -- High-Intensity Focused Ultrasound -- Reprinted from: Pharmaceutics 2020, 12, 974, doi:10.3390/pharmaceutics12100974 153 -- Ragnhild Haugse, Anika Langer, Elisa Thodesen Murvold, Daniela Elena Costea, Bjørn Tore -- Gjertsen and Odd Helge Gilja et al. -- Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, -- Fibroblasts and Endothelial Cells -- Reprinted from: Pharmaceutics 2020, 12, 1058, doi:10.3390/pharmaceutics12111058 169 -- B ´arbara Pinto, Ana C. Henriques, Patr´ıcia M. A. Silva and Hassan Bousbaa -- Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research -- Reprinted from: Pharmaceutics 2020, 12, 1186, doi:10.3390/pharmaceutics12121186 187 -- Laia Hernandez-Oller, Joaquin Seras-Franzoso, Fernanda Andrade, Diana Rafael, Ibane -- Abasolo and Petra Gener et al. -- Extracellular Vesicles as Drug Delivery Systems in Cancer -- Reprinted from: Pharmaceutics 2020, 12, 1146, doi:10.3390/pharmaceutics12121146 225 -- Jaeduk Park, Hyuk Lee, Yu Seok Youn, Kyung Taek Oh and Eun Seong Lee -- Tumor-Homing pH-Sensitive Extracellular Vesicles for Targeting Heterogeneous Tumors -- Reprinted from: Pharmaceutics 2020, 12, 372, doi:10.3390/pharmaceutics12040372 245 -- Levente E. D ´okus, Eszter Lajk ´o, Ivan Ranelovi´c, Di ´ana Mez ˝o, Gitta Schlosser and L ´aszl ´o -- K ˝ohidai et al. -- Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to -- PANC-1 Pancreatic Cancer -- Reprinted from: Pharmaceutics 2020, 12, 576, doi:10.3390/pharmaceutics12060576 261 -- Ayman Abouzayed, Hanna Tano, Abel Nagy, Sara S. Rinne, Fadya Wadeea and Sharmishtaa ´ -- Kumar et al. -- Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the -- Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer -- Reprinted from: Pharmaceutics 2020, 12, 977, doi:10.3390/pharmaceutics12100977 281 -- Adriana G. Quiroz-Reyes, Jose F. Islas, Paulina Delgado-Gonzalez, Hector Franco-Villarreal -- and Elsa N. Garza-Trevi ˜no -- Therapeutic Approaches for Metastases from Colorectal Cancer and Pancreatic Ductal -- Carcinoma -- Reprinted from: Pharmaceutics 2021, 13, 103, doi:10.3390/pharmaceutics13010103 299 -- Joseph J. Noh, Myeong-Seon Kim, Young-Jae Cho, Soo-Young Jeong, Yoo-Young Lee and -- Ji-Yoon Ryu et al. -- Anti-Cancer Activity of As4O6 and its Efficacy in a Series of Patient-Derived Xenografts for -- Human Cervical Cancer -- Reprinted from: Pharmaceutics 2020, 12, 987, doi:10.3390/pharmaceutics12100987 323 -- Guillaume Sicard, Cl´ement Paris, Sarah Giacometti, Anne Rodallec, Joseph Ciccolini and -- Palma Rocchi et al. -- Enhanced Antisense Oligonucleotide Delivery Using Cationic Liposomes Grafted with -- Trastuzumab: A Proof-of-Concept Study in Prostate Cancer -- Reprinted from: Pharmaceutics 2020, 12, 1166, doi:10.3390/pharmaceutics12121166 337 -- Guillaume Sicard, Fr ´ed ´eric Fina, Raphaelle Fanciullino, Fabrice Barlesi and Joseph Ciccolini -- Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for -- Combinatorial Immunotherapy -- Reprinted from: Pharmaceutics 2020, 12, 758, doi:10.3390/pharmaceutics12080758 353 -- Jong Hyuk Byun, In-Soo Yoon, Yong Dam Jeong, Sungchan Kim and Il Hyo Jung -- A Tumor-Immune Interaction Model for Synergistic Combinations of Anti PD-L1 and Ionizing -- Irradiation Treatment -- Reprinted from: Pharmaceutics 2020, 12, 830, doi:10.3390/pharmaceutics12090830 369.